JP2016504400A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504400A5
JP2016504400A5 JP2015552060A JP2015552060A JP2016504400A5 JP 2016504400 A5 JP2016504400 A5 JP 2016504400A5 JP 2015552060 A JP2015552060 A JP 2015552060A JP 2015552060 A JP2015552060 A JP 2015552060A JP 2016504400 A5 JP2016504400 A5 JP 2016504400A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
aryl
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015552060A
Other languages
English (en)
Japanese (ja)
Other versions
JP6276289B2 (ja
JP2016504400A (ja
Filing date
Publication date
Priority claimed from GBGB1300435.3A external-priority patent/GB201300435D0/en
Application filed filed Critical
Publication of JP2016504400A publication Critical patent/JP2016504400A/ja
Publication of JP2016504400A5 publication Critical patent/JP2016504400A5/ja
Application granted granted Critical
Publication of JP6276289B2 publication Critical patent/JP6276289B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015552060A 2013-01-10 2014-01-10 ベンジリデングアニジン誘導体、及びタンパク質ミスフォールディング疾患を治療するための治療的使用 Active JP6276289B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1300435.3 2013-01-10
GBGB1300435.3A GB201300435D0 (en) 2013-01-10 2013-01-10 Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
PCT/EP2014/050422 WO2014108520A1 (en) 2013-01-10 2014-01-10 Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases

Publications (3)

Publication Number Publication Date
JP2016504400A JP2016504400A (ja) 2016-02-12
JP2016504400A5 true JP2016504400A5 (cg-RX-API-DMAC7.html) 2017-01-05
JP6276289B2 JP6276289B2 (ja) 2018-02-07

Family

ID=47757796

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015552060A Active JP6276289B2 (ja) 2013-01-10 2014-01-10 ベンジリデングアニジン誘導体、及びタンパク質ミスフォールディング疾患を治療するための治療的使用

Country Status (21)

Country Link
US (4) US9682943B2 (cg-RX-API-DMAC7.html)
EP (2) EP3115357B1 (cg-RX-API-DMAC7.html)
JP (1) JP6276289B2 (cg-RX-API-DMAC7.html)
KR (1) KR102166665B1 (cg-RX-API-DMAC7.html)
CN (1) CN105189452B (cg-RX-API-DMAC7.html)
AU (2) AU2014204831C1 (cg-RX-API-DMAC7.html)
CA (1) CA2896976C (cg-RX-API-DMAC7.html)
DK (1) DK2943467T3 (cg-RX-API-DMAC7.html)
ES (2) ES2594378T3 (cg-RX-API-DMAC7.html)
GB (1) GB201300435D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20161208T1 (cg-RX-API-DMAC7.html)
HU (1) HUE030848T2 (cg-RX-API-DMAC7.html)
IL (1) IL239629B (cg-RX-API-DMAC7.html)
LT (1) LT2943467T (cg-RX-API-DMAC7.html)
MX (1) MX370491B (cg-RX-API-DMAC7.html)
PL (1) PL2943467T3 (cg-RX-API-DMAC7.html)
PT (1) PT2943467T (cg-RX-API-DMAC7.html)
RS (1) RS55185B1 (cg-RX-API-DMAC7.html)
RU (1) RU2654910C2 (cg-RX-API-DMAC7.html)
SI (1) SI2943467T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014108520A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300435D0 (en) 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
US10905663B2 (en) 2013-03-05 2021-02-02 The University Of Chicago Treatment of demyelinating disorders
PT3164123T (pt) * 2014-07-02 2020-07-24 Inflectis Bioscience Novas utilizações terapêuticas de derivados de benzilidenoguanidina para o tratamento de proteopatias
EP3280405B1 (en) * 2015-04-08 2021-07-07 United Kingdom Research and Innovation Inhibitors and their uses
US9501793B1 (en) * 2015-06-04 2016-11-22 Herofi, Inc. Archetecture and associated methodology for data standardization and utilization in retail industry applications
US10675257B2 (en) 2015-07-31 2020-06-09 Inflectis Bioscience Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent
US20180230105A1 (en) 2017-01-13 2018-08-16 Regents Of The University Of Minnesota Therapeutic compounds
US11166464B2 (en) * 2017-03-06 2021-11-09 The United States Of America, As Represented By The Secretary Of Agriculture Self-assembled active agents
EP3790539A1 (en) 2018-05-09 2021-03-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies
CN113072467B (zh) * 2021-03-24 2022-04-12 南方医科大学 含取代胍基衍生物及其在制备破骨细胞分化抑制剂上的应用
WO2024105168A1 (en) 2022-11-18 2024-05-23 Inflectis Bioscience Novel combinations useful for the treatments of als
US20240293343A1 (en) 2023-02-13 2024-09-05 Inflectis Bioscience Benzylideneaminoguanidine derivatives as NR2B-selective NMDA receptor antagonists and their therapeutic applications
KR20250157531A (ko) * 2023-03-16 2025-11-04 교토후고리츠다이가쿠호진 Ampk 활성화 및/또는 chop 억제에 의한 치료가 가능한 질환 및 장애의 치료를 위한 sephin1 및 관련 화합물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1223492A (en) * 1967-10-13 1971-02-24 American Home Prod Guanidines
US3541218A (en) * 1969-06-18 1970-11-17 Lilly Co Eli Omicron-fluorobenzylaminoguanidine for diabetes
SE7607653L (sv) 1976-07-05 1978-01-06 Haessle Ab Substituerade triazoler
JPH06510760A (ja) * 1991-08-27 1994-12-01 ジ・アップジョン・カンパニー 代謝障害および代謝の治療法
PT793646E (pt) * 1994-11-23 2002-03-28 Biovitrum Ab Carboxilatos de aminoguanidina destinados ao tratamento de diabetes mellitus nao-insulinodependente
US6335339B1 (en) 1998-01-13 2002-01-01 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
AU7802700A (en) 1999-10-06 2001-05-10 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
GB0019357D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
US6518269B1 (en) 2000-07-28 2003-02-11 University Of Arizona Foundation Cancer treatment
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
FR2812812B1 (fr) 2000-08-08 2002-10-11 Philippe Gorny Medicament destine notamment a combattre les dysfonctions sexuelles
MXPA06003276A (es) * 2003-09-25 2006-06-08 Acadia Pharm Inc Tratamiento de dolor neuropatico con agonistas de receptor de neuropeptido ff 2.
CN1875271A (zh) * 2003-09-25 2006-12-06 阿卡蒂亚药品公司 用神经肽ff受体2激动剂治疗神经痛
EP1908465B1 (en) * 2006-10-04 2009-04-29 Centre National De La Recherche Scientifique (Cnrs) Use of chlorine guanabenz derivatives for treating prion-based diseases
EP1908464A1 (en) * 2006-10-04 2008-04-09 Centre National De La Recherche Scientifique (Cnrs) Use of chlorine guanabenz derivatives for treating polyglutamine expansion associated diseases
WO2008091681A2 (en) 2007-01-23 2008-07-31 Housey Gerard M Theramutein modulators
WO2011039735A2 (en) 2009-10-02 2011-04-07 Consiglio Nazionale Delle Ricerche Compounds with ddx3 inhibitory activity and uses thereof
US20130085133A1 (en) 2010-02-08 2013-04-04 Sourthern Research Institute Office of Commercialization and Intellectual Prop. Anti-viral treatment and assay to screenfor anti-viral agent
BR112013001217B1 (pt) 2010-07-20 2019-11-19 Vestaron Corp composto, composição inseticida contendo o mesmo, e, método para controlar insetos
US20130274235A1 (en) * 2010-10-08 2013-10-17 The General Hospital Corporation Treatment of motor neuron disease
GB201300435D0 (en) * 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases

Similar Documents

Publication Publication Date Title
JP2016504400A5 (cg-RX-API-DMAC7.html)
RU2015127827A (ru) Производные бензилиденгуанидина и их терапевтическое применение для лечения заболеваний, связанных с неправильным сворачиванием белков
JP2017509586A5 (cg-RX-API-DMAC7.html)
AR122902A2 (es) Compuestos terapéuticamente activos y sus métodos de preparación
JP2017071634A5 (cg-RX-API-DMAC7.html)
JP2016506960A5 (cg-RX-API-DMAC7.html)
JP2016505637A5 (cg-RX-API-DMAC7.html)
JP2014521688A5 (cg-RX-API-DMAC7.html)
JP2013537203A5 (cg-RX-API-DMAC7.html)
JP2016503797A5 (cg-RX-API-DMAC7.html)
JP2016506961A5 (cg-RX-API-DMAC7.html)
PE20141282A1 (es) Derivados de 8-carbamoil-2-(2,3-pirid-6-ilo di sustituido)-1,2,3,4-tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
JP2017533968A5 (cg-RX-API-DMAC7.html)
JP2013533879A5 (cg-RX-API-DMAC7.html)
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
JP2014511891A5 (cg-RX-API-DMAC7.html)
JP2014511892A5 (cg-RX-API-DMAC7.html)
JP2016517417A5 (cg-RX-API-DMAC7.html)
JP2016506962A5 (cg-RX-API-DMAC7.html)
JP2017504635A5 (cg-RX-API-DMAC7.html)
JP2016505614A5 (cg-RX-API-DMAC7.html)
JP2016507575A5 (cg-RX-API-DMAC7.html)
JP2016531126A5 (cg-RX-API-DMAC7.html)
JP2015500842A5 (cg-RX-API-DMAC7.html)
JP2016513696A5 (cg-RX-API-DMAC7.html)